JAK inhibitors like baricitinib and ritlecitinib have gotten most of the attention in alopecia areata treatment over the past few years, and for good reason — they’re the first FDA-approved options for an autoimmune condition that used to have none. But a different drug, working through an entirely different immune pathway, just reported real trial data of its own. Bempikibart isn’t approved yet, and it isn’t interchangeable with JAK inhibitors, but it’s worth understanding if you’ve been following alopecia areata treatment options.
A Different Mechanism, Not Just a New Brand
Bempikibart (also known by its development code, ADX-914) is a fully human monoclonal antibody developed by Q32 Bio, in partnership with BMS, that targets the IL-7 receptor alpha (IL-7Rα). Blocking that receptor interrupts signaling from both IL-7 and thymic stromal lymphopoietin (TSLP), two separate immune signals involved in the T-cell activity that drives alopecia areata. That’s a genuinely different target from baricitinib, ritlecitinib, and upadacitinib, which all work by blocking the JAK/STAT signaling pathway. In practice, this means bempikibart is being studied as an option for people whose alopecia areata doesn’t respond well to JAK inhibitors, or who can’t tolerate them — not as a simple substitute for people already doing well on one.
What the Phase 2a Trial Actually Found
The SIGNAL-AA Part B trial enrolled 33 adults with severe to very severe alopecia areata — baseline SALT scores of 50 to 100, meaning at least half the scalp affected — and notably, 36.4% of participants had already tried a JAK inhibitor without adequate response. At week 36: the average SALT score (a standard measure of scalp hair loss) dropped 35.3% from baseline. Among evaluable patients, 40.0% reached SALT-20, meaning at least 80% scalp hair coverage; 44.0% reached SALT-30 and SALT-50 response thresholds. There were no serious adverse events and no grade 3 or higher treatment-related events. The most common side effect was injection-site reactions, in 36.3% of patients, generally mild and resolving within a day.
What These Numbers Actually Mean
A 35.3% average SALT reduction over 36 weeks in a population where more than a third had already failed JAK inhibitor treatment is a meaningful early signal, not a dramatic breakthrough. This is Phase 2a data — a relatively small, early-stage trial designed to establish whether a drug shows enough promise and safety to justify larger trials, not a result that predicts exactly how it will perform in the general alopecia areata population. Bempikibart received FDA Fast Track designation in April 2025, which speeds up the regulatory review process for drugs addressing unmet medical needs, but Fast Track status is not the same as approval, and there’s no confirmed timeline yet for when (or if) bempikibart will reach the market.
How This Fits Into the Alopecia Areata Treatment Landscape
Alopecia areata research has moved fast in 2026, and it’s worth being clear about what’s actually available versus what’s still in trials. Baricitinib and ritlecitinib are FDA-approved, prescribable treatments today. Upadacitinib has EU approval with a U.S. decision pending. Bempikibart, along with several other candidates, remains investigational — something to discuss with a dermatologist as a possible future or trial option, not something to request as a current treatment. If you have alopecia areata and current treatments aren’t working well for you, ask your dermatologist about clinical trial enrollment rather than trying to source an unapproved drug independently.
Why Non-Response to JAK Inhibitors Happens at All
Roughly a quarter of alopecia areata patients don’t respond meaningfully to JAK inhibitor treatment, and researchers don’t yet have a reliable way to predict in advance who will fall into that group. One working theory is that alopecia areata isn’t immunologically identical in every patient — the T-cell activity that drives it may be triggered or sustained through more than one signaling pathway, which would explain why a drug blocking JAK/STAT signaling helps most patients but not all of them. That’s part of why a drug like bempikibart, working through the separate IL-7Rα/TSLP pathway, matters beyond just adding another name to the list — if the biology really does split into more than one contributing mechanism, having treatment options that target different pathways gives non-responders to one class an actual second avenue, rather than just a different formulation of the same approach.
Q32 Bio, bempikibart’s developer, has partnered with BMS to advance the drug through further trials, which is a meaningful signal of continued investment but still doesn’t change the regulatory timeline — a Phase 3 program, if it proceeds, would typically take a couple of years before any approval decision.
Frequently Asked Questions
Is bempikibart available to patients right now?
No. It’s still in clinical trials (Phase 2a completed, with next steps toward Phase 3 expected). It is not an FDA-approved treatment and isn’t available by prescription.
Is bempikibart better than JAK inhibitors?
The trial data isn’t designed to make that comparison directly, and the two drug classes haven’t been tested head-to-head. Bempikibart’s real value may end up being as an option for people who don’t respond to JAK inhibitors, given that over a third of trial participants fell into that category and still showed response.
How is bempikibart administered?
It’s given by injection, unlike the oral JAK inhibitors currently approved for alopecia areata, which is part of why injection-site reactions were the most common side effect reported.
What happens next in bempikibart’s development?
Following the positive Phase 2a Part B topline results, the next step is typically a larger Phase 3 program to confirm efficacy and safety across a bigger, more diverse patient group. There’s no publicly confirmed Phase 3 start date as of this writing, and any eventual FDA approval decision would follow completion of that larger trial program, not the Phase 2a data alone.
Final Thoughts
Bempikibart adds a genuinely new mechanism to alopecia areata’s treatment pipeline, with early data suggesting it may help people who don’t respond to existing JAK inhibitor options. It’s promising, early-stage research — not a current treatment, and any alopecia areata diagnosis and treatment decision should go through a dermatologist. For a full breakdown of the treatments actually available today, see Gemifys’s guide to alopecia areata treatment in 2026 and how JAK inhibitors compare to minoxidil and finasteride.
For more hair-loss research explained in plain terms, browse the Hair Care section on gemifys.com.
